Hepatitis C Virus and Human Immunodeficiency Virus Coinfection in an Urban Population: Low Eligibility for Interferon Treatment

Fleming, Catherine A.; Craven, Donald E.; Thornton, David; Tumilty, Sheila; Nunes, David
January 2003
Clinical Infectious Diseases;1/1/2003, Vol. 36 Issue 1, p97
Academic Journal
Reports that hepatitis C virus and human immunodeficiency virus coinfected people in an urban population in the U.S. had low eligibility for interferon and ribavirin treatment. Percentage of people eligible and ineligible for treatment out of the total number of people evaluated Barriers in treatment eligibility.


Related Articles

  • Substrate recognition by norovirus polymerase: microsecond molecular dynamics study. Maláč, Kamil; Barvík, Ivan // Journal of Computer-Aided Molecular Design;Apr2013, Vol. 27 Issue 4, p373 

    Molecular dynamics simulations of complexes between Norwalk virus RNA dependent RNA polymerase and its natural CTP and 2dCTP (both containing the O5′-C5′-C4′-O4′ sequence of atoms bridging the triphosphate and sugar moiety) or modified coCTP ( C5′...

  • Emergence of genetically variant Hepatitis C virus population in response to increased antiviral drug pressure, Pakistan. Ali, Muhammad; Rehman, Irshad; Idrees, Muhammad // Virus Genes;Jun2014, Vol. 48 Issue 3, p543 

    Mutations in NS5B gene of Hepatitis C virus (HCV) have been reported in patients undergoing antiviral therapy. In the present study, we report emerging clade of HCV-3a in patients administered with IFN plus ribavirin therapy for 24 weeks and having low viral loads (<250 IU/mL). Mutations...

  • Inhibitors of the Hepatitis C Virus RNA-Dependent RNA Polymerase NS5B. Powdrill, Megan H.; Bernatchez, Jean A.; Götte, Matthias // Viruses (1999-4915);Oct2010, Vol. 2 Issue 10, p2169 

    More than 20 years after the identification of the hepatitis C virus (HCV) as a novel human pathogen, the only approved treatment remains a combination of pegylated interferon-a and ribavirin. This rather non-specific therapy is associated with severe side effects and by far not everyone...

  • Persistence of Hepatitis C RNA in Liver Allografts Is Associated with Histologic Progression Independent of Serologic Viral Clearance. Ghabril, M.; Dickson, R. C.; Krishna, M.; Lloyd, R.; Aranda-Michel, J.; Keaveny, A.; Satyanarayana, R.; Bonatti, H. // Journal of Transplantation;2009, p1 

    Background. Hepatitis C virus (HCV) nondetectability in the liver may predict a sustained viral response (SVR) in patients with an end of treatment response. HCV RNA can be detected in liver tissue by in situ hybridization (ISH). Aim. To determine if HCV nondetectability in liver allografts by...

  • New Expensive Treatments for Hepatitis C Infection. Brennan, Troyen; Shrank, William // JAMA: Journal of the American Medical Association;8/13/2014, Vol. 312 Issue 6, p593 

    The article discusses changes in the treatment options for hepatitis C virus (HCV) infection. Topics discussed include an overview of past treatment courses involving the drugs pegylated interferon and ribavirin, the use of polymerase inhibitors as the standard course of treatment in 2014, and...

  • Once-daily simeprevir with peginterferon and ribavirin for treatment-experienced HCV genotype 1-infected patients in Japan: the CONCERTO-2 and CONCERTO-3 studies. Izumi, Namiki; Hayashi, Norio; Kumada, Hiromitsu; Okanoue, Takeshi; Tsubouchi, Hirohito; Yatsuhashi, Hiroshi; Kato, Mai; Ki, Rito; Komada, Yuji; Seto, Chiharu; Goto, Shoichiro // Journal of Gastroenterology;May2014, Vol. 49 Issue 5, p941 

    Background: Efficacy of available therapies for patients with HCV who have previously failed treatment is limited. Two Phase III, open-label trials in Japan investigated efficacy and safety of simeprevir and peginterferon-α-2a/ribavirin (PR) combination therapy in treatment-experienced...

  • Peginterferon Alfa-2b and Ribavirin for 12 vs. 24 Weeks in HCV Genotype 2 or 3. Mangia, Alessandra; Santoro, Rosanna; Minerva, Nicola; Ricci, Giovanni L.; Carretta, Vito; Persico, Marcello; Vinelli, Francesco; Scotto, Gaetano; Bacca, Donato; Annese, Mauro; Romano, Mario; Zechini, Franco; Sogari, Fernando; Spirito, Fulvio; Andriulli, Angelo // New England Journal of Medicine;6/23/2005, Vol. 352 Issue 25, p2609 

    This article presents a study on the use of peginterferon alfa-2b and ribavirin for treatment of patients with chronic hepatitis C virus (HCV). The purpose of the study is to determine the ultimate course of medication to patients with HCV genotype 2 or 3. The study design is explained along...

  • Genetic variability of the core protein in hepatitis C virus genotype 4 in Saudi Arabian patients and its implication on pegylated interferon and ribavirin therapy. Alhamlan, Fatimah S.; Al-Ahdal, Mohammed N.; Khalaf, Nisreen Z.; Abdo, Ayman A.; Sanai, Faisal M.; Al-Ashgar, Hamad I.; ElHefnawi, Mahmoud; Zaid, Amina; Al-Qahtani, Ahmed A. // Journal of Translational Medicine;2014, Vol. 12 Issue 1, p1 

    Background Hepatitis C virus (HCV) shows a remarkable genetic diversity, contributing to its high persistence and varied susceptibilities to antiviral treatment. Previous studies have reported that the substitution of amino acids in the HCV subgenotype 1b core protein in infected patients is...

  • Endogenous IFNγ in chronic HCV genotype 4 patients treated with PEG-IFNα and ribavirin. Sadeq, Refaat; Mohtady, Heba; Al Badawy, Nissreen; Ibrahim, Salwa; Omar, Abdul Rahman; Husseiny, Mohamed I.; El Zowalaty, Mohamed // Journal of Infection in Developing Countries;2013, Vol. 7 Issue 11, p859 

    Introduction: Hepatitis C virus (HCV) infections remain an increasingly prevalent and emergent health problem worldwide, causing a wide spectrum of liver diseases. Combination therapy with pegylated interferon (PEG-IFN) of peginterferon alfa-2a and oral ribavirinis currently recognized as the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics